‘The preliminary results of a clinical trial suggest a new treatment for Covid-19 dramatically reduces the number of patients needing intensive care, according to the UK company that developed it. The treatment from Southampton-based biotech Synairgen uses a protein called interferon beta which the body produces when it gets a viral infection... The initial findings suggest the treatment cut the odds of a Covid-19 patient in hospital developing severe disease - such as requiring ventilation - by 79%.’
Read here (BBC, July 20, 2020
